BioSpace News Archive

Confo Therapeutics announced that it has entered a collaboration agreement with Daiichi Sankyo for the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases.

Comanche Biopharma Corp., a biopharmaceutical company, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for Comanche’s novel, siRNA therapy to treat preeclampsia.

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, reported its financial results for the fiscal year ended December 31, 2022 and provided a business update.

Clearpath Technologies, LLC, a wholly owned subsidiary of Authentic, Inc. announced the launch of five new native integrations with leading electronic medical record platforms, including Allscripts, Athena Health, Cerner, Epic, and NextGen.

With more than 10 years of experience in protein development, ACROBiosystems has continuously demonstrated its strength in developing products and services throughout the entire drug development process.

Trevena, Inc. reported its financial results for the fourth quarter ended December 31, 2022 and provided an overview of its recent operational highlights.

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today reported recent business progress and financial results for the fourth quarter and full-year ended December 31, 2022.

Alaunos Therapeutics, Inc., a leading T-cell receptor cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, announced the appointment of Robert J. Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company’s Board of Directors, effective immediately.

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease (CAD) and prevention of stroke today announced financial and operating results for the fourth quarter ended December 31, 2022.

Nanoscope Therapeutics Inc., today announced topline results from the Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation.